2026 AACR Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026. Highlights in this video include: • T-DXd plus olaparib demonstrated that schedule matters: Gapped olaparib dosing improved feasibility, reduced hematologic toxicity, and preserved strong antitumor activity in HER2-expressing tumors. • The EGFR-targeted ADC SYS6010 produced meaningful activity with manageable toxicity, particularly in EGFR antibody-naive patients, raising the possibility of extending similar ADC strategies into EGFR-expressing GU tumors such as bladder, urethral, and penile cancers.